Improving combination chemotherapeutic regimens is particularly important in triple negative breast cancer, as cells do not over‐express the common receptors (progesterone (PR), estrogen (ER), and human epidermal growth factor (HER2)) which are the common therapeutic targets for other breast cancer types.1, 21 While triple negative breast cancer patients are typically responsive to chemotherapy, patients with metastasized triple negative breast cancer have poor prognosis. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.